Registry of Lobbyists

Registration - In-house Organization

Innovative Medicines Canada / Médicaments novateurs Canada / Bettina Hamelin, President

Registration Information

In-house Organization name: Innovative Medicines Canada / Médicaments novateurs Canada
Previous in-house organization names
Responsible Officer Name: Bettina Hamelin, President 
Responsible Officer Change History
Initial registration start date: 2004-08-19
Registration status: Active
Registration Number: 957857-371

Associated Communications

Total Number of Communication Reports: 958

Monthly communication reports in the last 6 months: 40

Version 4 of 117 (2006-02-07 to 2006-04-18)

Version 4 of 117 (2006-02-07 to 2006-04-18) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Organization Information

Organization: Rx&D, Canada's Research Based Pharmaceutical Companies
55 Metcalfe Street
Suite 1220
Ottawa, ON  K1P 6L5
Canada
Telephone number: 613-236-0455  Ext.: 425
Fax number: 613-236-6756  
Responsible officer name and position during the period of this registration: RUSSELL WILLIAMS, PRESIDENT  
 
Description of the organization's activities: Canada's Research-Based Pharmaceutical Companies (Rx&D) is the industry association of Canada's research-based pharmaceutical industry. The companies that make up the membership of Rx&D are engaged in the research and development, production, marketing, and servicing of prescription and non-prescription pharmaceutical products. Rx&D members employ more than 22,000 people accross Canada. Comprised of companies of all sizes, Rx&D's membershio reflects the international scope of the pharmaceutical industry and includes the Canadian operations of domestic firms. As well as those with headquarters in other countries, Rx&D membership is currently made up of approximately 50 member companies.
Organization's membership or classes of membership: (a) Full Membership: Full membership is open to innovative pharmaceutical Persons which research, develop, manufacture and/or distribute pharmaceutical prescription preparations under their own labels in Canada. (b) Biopharmaceutical Membership: Biopharmaceutical membership is open to Persons who are engaged, for profit, in research and development of pharmaceutical products and/or biopharmaceutical health care products with the aim of producing, manufacturing or distributing the same under its own label.(c) Medical Research Affiliate Membership: Medical research affiliate membership is open to non-profit organizations engaged in research which have a relationship or are connected with hospitals, universities, research institutes, recognized health/disease organizations, or divisions or units thereof, whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects, and who are engaged in health research.(d) Associate Membership: Associate membership is open to Persons who do not qualify under any of the foregoing membership categories and whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects (»Associate Members«). Without limiting the generality of the foregoing, Associate Members may include contract research organizations, contract manufacturing organizations and clinical research organizations who supply goods and/or services to Full Members or Biopharmaceutical Members and other stakeholder groups.
 
Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Organization

Name: Charles Bergeron
Position title: Advisor
Public offices held: Yes
 
Name: Marianne Goodwin
Position title: Director, Federal Government Affairs/FPT Relations
Public offices held: Yes
 
Name: Brigitte Nolet
Position title: Vice President, Federal Government Affairs/FPT Relations
Public offices held: Yes
 
Name: Aileen O'Rafferty
Position title: Federal and Territorial Affairs
Public offices held: No
 
Name: Walter Robinson
Position title: Vice President, Provincial Affairs
Public offices held: Yes
 
Name: Russell Williams
Position title: President
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Citizenship and Immigration Canada, Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), House of Commons, Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Auditor General, Office of the Information and Privacy Commissioner (OIPC), Patented Medicine Prices Review Board (PMPRB), PMO, Privy Council Office (PCO), Public Works and Government Services Canada, Revenue Canada (RC), Senate (Senators), Solicitor General Canada (SGC), Statistics Canada (StatCan), Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Arts and Culture, Broadcasting, Constitutional Issues, Consumer Issues, Defence, Education, Employment and Training, Energy, Environment, Financial Institutions, Fisheries, Forestry, Government Procurement, Health, Immigration, Industry, Infrastructure, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Labour, Mining, Regional Development, Science and Technology, Small Business, Sports, Taxation and Finance, Telecommunications, Tourism, Transportation
 
Subject Matter: Retrospective: Industry Canada: political/bureaucrat - innovation strategy, Patented Medicines (PM) Notice of Compliance (NOC) regulations, cross-border trade, budget, issues affecting health and pharmaceuticia industries, and biotechnology.Health Canada: innovation strategy, PM (NOC) regulations, cross-border trade, international aid programs.
Subject Matter: Prospective: Treasury Board: Smart RegulationsIndustry Canada: innovation issues, PM (NOC) regulations, pharmaceutical and biotechnology R&D issues, smart regulations, cross-border trade, patent policy. Health Canada: drug safety, data regulations, innovation issues, cross border trade, drug approval, counterfeit drugs, and national pharmaceutical strategy.Foreign Affairs: ongoing international issues, cross-border trade.Finance: Budget/budget update
 

Details Regarding the Identified Subject Matter

Categories Description
Bill or Resolution Bill C-83, An Act to Amend the Food and Drugs Act (drug export restrictions)
Legislative Proposal Budget/budget update
Regulation Food and Drug Regulations (Data Protection) Patented Medicines (Notice of Compliance) Regulations
Policy or Program National Pharmaceutical Strategy




Date Modified: